D. Simpson

发表

Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.

R. Elstrom, W. Novotny, P. Marlton, 2019, Blood.

A rapid flow cytometric assay to detect CD4+ and CD8+ T‐helper (Th) 0, Th1 and Th2 cells in whole blood and its application to study cytokine levels in atopic dermatitis before and after cyclosporin therapy

H. Chapel, S. Powell, D. Simpson, 2001, The British journal of dermatology.

Drug therapy for acute graft-versus-host disease prophylaxis.

D. Simpson, D. Simpson, 2000, Journal of hematotherapy & stem cell research.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

A. Palumbo, A. Hui, P. Ganly, 2016, The New England journal of medicine.

In vivo purging with rituximab prior to collection of stem cells for autologous transplantation in chronic lymphocytic leukemia.

A. Raptis, H. Klingemann, L. Berkahn, 2002, Journal of hematotherapy & stem cell research.

Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma

R. Tsang, A. Keating, R. Abraham, 1999, Bone Marrow Transplantation.

High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation

D. Horsman, S. Nantel, M. Barnett, 1998, Bone Marrow Transplantation.

PS1159 POOLED ANALYSIS OF SAFETY DATA FROM MONOTHERAPY STUDIES OF THE BRUTON TYROSINE KINASE (BTK) INHIBITOR, ZANUBRUTINIB (BGB-3111), IN B-CELL MALIGNANCIES

W. Novotny, P. Marlton, A. Roberts, 2019, HemaSphere.

A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association o

S. Opat, C. Tam, H. Prince, 2020, Pathology (Sydney).

Frontline treatment of elderly non transplant‐eligible multiple myeloma patients using CyBorD with or without thalidomide‐based consolidation: a retrospective multi‐centre analysis of real‐world data

Kevin Chen, Henry S H Chan, S. Jackson, 2019, British journal of haematology.

Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis

P. Richardson, S. Harrison, T. Facon, 2019, Clinical Lymphoma, Myeloma & Leukemia.